AzTrials
AzTrials

Tobacco UseText2QuitNCT07734727

Adaptation and Testing of a Novel Text-based Tobacco Cessation and Education Intervention in Kenyan Emergency Department Patients

A study testing Text2Quit-Kenya in people with Tobacco Use and Tobacco Use Cessation, run by Yale University at 1 site in Kenya.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

In this study, investigators will adapt and implement Text2Quit in a Kenyan ED population will increase knowledge and cessation. Investigators will use a mixed-methods, hybrid implementation-effectiveness approach to assess these outcomes. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Tobacco Use, Tobacco Use Cessation
What is being tested?
Text2Quit-Kenya
Could I receive a placebo?
No, everyone receives an active treatment
How many people
285 participants
Where
1 siteKenya
Study dates
Nov 2026to Jun 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Current tobacco users (self-identified smokers).
  • Presenting to the Emergency Department (ED) at Kenyatta National Hospital (KNH).
  • Own a mobile phone capable of receiving text messages.
  • Willing to quit tobacco use.
  • Able and willing to provide informed consent.

Who cannot join

  • Individuals unwilling or unable to provide consent.
  • Non-tobacco users.
  • Those without access to a mobile phone.
  • Patients who are critically ill or otherwise unable to participate (practically excluded at triage).

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Christine Ngaruiya, MD MSC DTMH contact

650-723-6576

cngaruiya@stanford.edu

Jessica Rayo, MS contact

559-759-4266

jrayo@stanford.edu

Kenya1 site, 1 recruiting
  • Kenyatta National Hospital

    Nairobi

    Recruiting

Other trials in Kenya

About this study

In this study, investigators will adapt and implement Text2Quit in a Kenyan ED population will increase knowledge and cessation. Investigators will use a mixed-methods, hybrid implementation-effectiveness approach to assess these outcomes. Results will inform a randomized, controlled trial in a nationally representative sample of EDs in future. This study will be the first to target tobacco use in this population, the first to use mobile cessation, and will contribute to advancing implementation science on tobacco cessation globally. It will also provide a novel approach to implementation for mHealth interventions, with findings that can be generalized to other Non-Communicable Diseases and risk factors, such as alcohol use, hypertension and diabetes.

Read the detailed description

Aim 1. To assess tobacco use and willingness to engage with mHealth for tobacco cessation targeting Kenyan ED patients.

Aim 2. To adapt the Text2Quit mHealth tool for use in the Kenya context using a participatory approach.

Aim 3. To pilot test Text2Quit-Kenya and assess its acceptability, feasibility, and efficacy.

The focus of this registration is Aim 3.

Being tested
Text2Quit-Kenya
Keywords
Kenya, Africa, Noncommunicable disease, global health
Medical subject headings
Tobacco Use, Tobacco Use Cessation, Noncommunicable Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Text2Quit-KenyaOther

    A text message-based mHealth tool addressing tobacco cessation. The program is organized around automated, bidirectional text messages timed for a user's quit date. Messages based on social cognitive theory prompt users to track smoking, report on cravings and on smoking status.

Study groups in NCT07734727
Study groupRoleWhat they receive
Text2Quit KenyaActive comparatorParticipants will receive the Text2Quit intervention
Receives: Other: Text2Quit-Kenya
ControlNo interventionStandard of care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Text2Quit Survey to assess efficacy

    Efficacy will be assessed by self-report binary quantitative outcome of tobacco use in past 7 days

    Measured: Baseline and 1 Month post intervention

  2. Exhaled Carbon Monoxide testing to assess efficacy

    Efficacy will be assessed by repeat exhaled Carbon Monoxide testing. Will be assessed using both a binary assessment with a cutoff of 10% and a continuous assessment of percent point prevalence

    Measured: Baseline, Month 1 and Month 6

Secondary outcomes (14)
  1. Percent enrollment

    Percent enrollment per arm using Reach RE-AIM Framework

    Measured: Baseline

  2. Adoption assessed using Adoption RE-AIM Framework

    This is a qualitative outcome. The measure will be assessed using a semi-structured interview guide informed by the RE-AIM Adoption framework. Interview transcripts will undergo thematic analysis to identify themes related to intervention adoption, future use, and perceived fit within the target community.

    Measured: up to Month 6

  3. Facililtators -Implementation

    Facililtators assessed using semi-structured qualitative interviews guided by the RE-AIM Implementation framework, with thematic analysis used to identify themes.

    Measured: up to Month 6

  4. Barriers-Implementation

    Barriers assessed using semi-structured qualitative interviews guided by the RE-AIM Implementation framework, with thematic analysis used to identify themes.

    Measured: up to Month 6

  5. Frequency of message delivery

    Frequency of message delivery using Implementation RE-AIM Framework

    Measured: up to Month 6

  6. Frequency of message read

    Frequency of message read using Implementation RE-AIM Framework

    Measured: Baseline, Month 1 and Month 6

  7. Frequency of response

    Absolute and proportion of response to interactive messages using Implementation RE-AIM Framework

    Measured: up to Month 6

  8. Maintenance assessed using RE-AIM Framework

    Assesses the long-term sustainability of an intervention by measuring two key levels: individual long-term effects and setting-level institutionalization.

    Measured: Month 6

  9. Cost

    Number of texts sent x cost per text to obtain individual user cost using Implementation RE-AIM Framework

    Measured: Month 6

  10. Tobacco Policies Knowledge

    Change in knowledge on tobacco policies using qualitative measure based on Efficacy RE-AIM Framework

    Measured: Baseline and Month 1

  11. Tobacco Harms Knowledge

    Change in knowledge on tobacco harms of use using qualitative measure based on Efficacy RE-AIM Framework. Mean count of correct responses to the tobacco harms knowledge items, with scores ranging from 0 to 5 (higher scores indicate greater knowledge).

    Measured: Baseline and Month 1

  12. Tobacco Use Frequency

    Frequency of tobacco use using Efficacy RE-AIM Framework

    Measured: Baseline and Month 1

  13. Mean Tobacco Cessation Attempts

    Mean number of tobacco cessation attempts using Efficacy RE-AIM Framework

    Measured: Baseline and Month 1

  14. Absolute Number Tobacco Cessation Attempts

    Absolute number of tobacco cessation attempts using Efficacy RE-AIM Framework

    Measured: Baseline and Month 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jul 2026
  2. Study startNov 2026 (estimated)
  3. Primary completionJun 2028 (estimated)
  4. Study completionJun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
285 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07734727
Sponsor's protocol ID
2000031446
Other IDs
R21DA052790
Acronym
Text2Quit
Status last verified
Oct 2026
First submitted
21 May 2026
Last updated
27 Oct 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Text2Quit-Kenya in people with Tobacco Use and Tobacco Use Cessation, run by Yale University at 1 site in Kenya.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Kenya. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Christine Ngaruiya, MD MSC DTMH (650-723-6576, cngaruiya@stanford.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Text2Quit Survey to assess efficacy (time frame: Baseline and 1 Month post intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in